Detection of infliximab levels and anti‐infliximab antibodies: a comparison of three different assays

Formation of antibodies to infliximab (ATI) inversely correlates with functional drug levels and clinical outcome. Comparison of drug levels and anti‐drug antibody monitoring is hampered by lack of standardisation.

[1]  E. Parussini.  Letter: detection of infliximab levels and anti‐infliximab antibodies — comparison of three different assays , 2013, Alimentary pharmacology & therapeutics.

[2]  J. Gisbert,et al.  Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response , 2012, Inflammatory bowel diseases.

[3]  B. Pariente,et al.  Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease , 2012, Inflammatory bowel diseases.

[4]  L. Croner,et al.  565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD) , 2012 .

[5]  P. Rutgeerts,et al.  1159 Results on the Optimisation Phase of the Prospective Controlled Trough Level Adapted Infliximab Treatment (TAXIT) Trial , 2012 .

[6]  U. Kopylov,et al.  The decline of anti‐drug antibody titres after discontinuation of anti‐TNFs: implications for predicting re‐induction outcome in IBD , 2012, Alimentary pharmacology & therapeutics.

[7]  Majid Abdulrahman Almadi,et al.  An unusual cause of upper gastrointestinal bleeding. , 2012, Gastroenterology.

[8]  L. Aarden,et al.  Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. , 2012, Journal of immunological methods.

[9]  L. Aarden,et al.  Differential effect of drug interference in immunogenicity assays. , 2011, Journal of immunological methods.

[10]  P. Rutgeerts,et al.  Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial , 2011, Gut.

[11]  K. Bendtzen,et al.  Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease , 2011, Alimentary pharmacology & therapeutics.

[12]  W. Reinisch,et al.  Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti‐TNF‐α therapy , 2011, Alimentary pharmacology & therapeutics.

[13]  L. Peyrin-Biroulet,et al.  Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review , 2011, The American Journal of Gastroenterology.

[14]  G Van Assche,et al.  Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment , 2011, Gut.

[15]  B. Dijkmans,et al.  The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept , 2010, Annals of the rheumatic diseases.

[16]  L. Aarden,et al.  A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. , 2010, Journal of immunological methods.

[17]  B. Dijkmans,et al.  Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis , 2010, Annals of the rheumatic diseases.

[18]  H. Tilg,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. , 2010, Journal of Crohn's & colitis.

[19]  P. Rutgeerts,et al.  The efficacy and safety of a third anti‐TNF monoclonal antibody in Crohn’s disease after failure of two other anti‐TNF antibodies , 2010, Alimentary pharmacology & therapeutics.

[20]  P. Rutgeerts,et al.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.

[21]  M. Silverberg,et al.  Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis , 2009, Gut.

[22]  G. Paintaud,et al.  An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab , 2009, Therapeutic drug monitoring.

[23]  K. Van Steen,et al.  Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.

[24]  B F Warren,et al.  European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. , 2008, Journal of Crohn's & colitis.

[25]  M. Silverberg,et al.  Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[26]  P. Goupille,et al.  An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Infliximab , 2006, Therapeutic drug monitoring.

[27]  B. Dijkmans,et al.  Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[28]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[29]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[30]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[31]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[32]  C. Franceschi,et al.  Microplate enzyme-linked immunosorbent assay in the study of the structural relationship between myosin light chains. , 1979, Journal of immunological methods.

[33]  B. Warner,et al.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.

[34]  S. Targan,et al.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.